Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 25;8:8157. doi: 10.1038/s41598-018-26383-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Treatment with OCA prevents hCLS formation and liver fibrosis in “inducible NASH model”. (a) Experimental protocol for examination of the preventive effect of OCA on hCLS formation and liver fibrosis in the inducible NASH model. (b) Hepatic mRNA expression levels of genes related to p53-regulated genes (p21 and Ctgf) 2 days after CCl₄ injection. (c) TUNEL staining of the liver 4 days after CCl₄ injection. (d) Histological analysis of hCLS using F4/80 immunostaining of the liver 7 days after CCl₄ injection. (e) Sirius red-positive area and representative Sirius red-stained liver sections 7 days after CCl₄ injection. Scale bars, 100 μm. CV, central veins. (f) Hepatic mRNA expression levels of genes related to fibrogenic factors (Tgfb1 and Col1a1) 7 days after CCl₄ injection. V, Vehicle. ^#p < 0.05, ^##p < 0.01. Vehicle-treated WT-SD group with olive oil injection, n = 10; vehicle-treated MC4R-WD group with CCl₄ injection, n = 10; OCA (10 mg/kg)-treated MC4R-WD group with CCl₄ injection, n = 10.

HHS Vulnerability Disclosure